Valencia Technologies Corporation (“Valencia” or the “Company”), a privately held company, announced it has retained PRIA Healthcare to assist in patient access for Valencia’s recently FDA approved proprietary product, eCoin®. eCoin is a leadless tibial nerve neurostimulator for the treatment of urge urinary incontinence (UUI), affecting over 60% of patients who suffer from Overactive Bladder (OAB).
PRIA has 10 years of experience assisting MedTech companies improve patient access to new medical devices. PRIA assists clients and develops patient-centric prior authorization and appeals programs that leverage clinical evidence and historical coverage decisions to best inform payors about the individual patient’s story. PRIA is a relentless advocate, dedicated to helping patients avoid the pitfalls of today’s medical insurance systems, helping more patients gain access to the care most likely to benefit them.
Mr. Clay Schwabe, VP, Business Development of PRIA Healthcare Management, stated, “PRIA leverages our experience in accelerating patient access to innovative medical solutions to help put therapy decisions back in the hands of the healthcare provider. We are especially excited to work with Valencia Technologies and eCoin. Our goal is to create more opportunities for indicated patients with bladder dysfunction to access this remarkable device.”
Ms. Ann Decker, Vice President, Reimbursement and Health Policy at Valencia Technologies, states, “We are excited to partner with PRIA as they help Valencia Technologies expand its eCoin technology into the marketplace through educating the numerous U.S. insurance companies on the clinically supported benefits of eCoin. Our confidence in the PRIA Team is a direct result of their many successes assisting other MedTech companies on this same journey with their emerging technologies.”